Cardiac 123I-MIBG scintigraphy: A window into the brain in Parkinsonism?
- 549 Downloads
Parkinson’s disease (PD) and other forms of neurodegenerative parkinsonism are multisystem disorders affecting several components of the central and peripheral nervous system.1,2 123I-meta-iodobenzylguanidine (123I-MIBG) is a false adrenergic neurotransmitter analog of norepinephrine, and cardiac 123I-MIBG scintigraphy can be used to evaluate noradrenergic postganglionic cardiac innervation. The use of cardiac 123I-MIBG scintigraphy has been established in the differential diagnosis of Lewy body diseases (PD and dementia with Lewy bodies). This is because patients with Lewy body diseases display a significantly lower myocardial 123I-MIBG uptake in comparison to healthy controls and individuals with other parkinsonian syndromes such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.3,4 However, the role of cardiac 123I-MIBG scintigraphy in parkinsonism is not limited to diagnosis. This imaging technique could also help detect early markers of neurodegeneration that predate the clinical diagnosis of PD, which is a prerequisite step in the development of disease-modifying therapies.5 A recent study by Takahashi et al showed a strong quantitative correlation between cardiac 123I-MIBG uptake and corresponding sympathetic axon loss in the cardiac tissue samples of 23 patients with autopsy-confirmed Lewy body diseases.6 This study confirmed the potential use of cardiac 123I-MIBG scintigraphy as a biomarker of cardiac sympathetic axon loss and Lewy body pathology. Moreover, cardiac 123I-MIBG scintigraphy may have significant clinical implications. Changes in 123I-MIBG uptake over time may help to characterize patients with PD, identify clinical phenotypes, and aid in predicting prognosis.7 Finally, cardiac 123I-MIBG scintigraphy may be used as a pathophysiological indicator in PD and related disorders. For the past 20 years, genetic research has led to the identification of several monogenic forms of PD and of numerous genetic risk factors, yet little is known about the cardiac autonomic innervation in these patients.8
This study by De Rosa et al also confirms that cardiac 123I-MIBG scintigraphy enables the study of the extracranial Lewy body type-degeneration in Lewy body diseases. Indeed, the majority of PD patients with mutations in the PARK2 gene do not exhibit the classical neuropathological markers of PD and the presence of Lewy body in PARK2 is uncommon and seemingly associated with later onset of disease, similar to idiopathic PD.9,10 The absence of cardiac sympathetic denervation in PARK2 has been supported by postmortem examination of cardiac tissues revealing that TH-immunoreactive nerve fibers in the epicardium were preserved in 3 patients with PARK2.11 Interestingly, 123I-MIBG uptake was abnormal in 4 out of 6 patients with single parkin mutations, which may suggest that these patients have cerebral and extracranial Lewy body pathology. Lewy bodies have been reported in PD patients with heterozygous parkin mutations12 and several explanations have been proposed for the inconsistent presence of Lewy bodies in parkin diseases: incidental Lewy bodies in older patients, a lack of the mechanisms necessary to clear protein accumulation, and residual ligase activity associated with the partial loss of parkin ubiquitin E3 ligase function.10 De Rosa et al speculate that a single parkin gene mutation in the setting of abnormal 123I-MIBG uptake may be a susceptibility factor for idiopathic PD. On the other hand, the authors suggest that the HET cases with normal myocardial scintigraphy might carry mutations within the promoter on the second allele, not identified by the molecular genetic techniques, or might carry additional mutations in genes that interact with parkin in common biological processes. This group of patients may be more similar to PARK2 patients.
In summary, we believe that cardiac 123I-MIBG scintigraphy is a window into the brain in patients with parkinsonism and provides valuable information about the pathology and the pathophysiology of different parkinsonian disorders. We share the authors’ point of view that further knowledge of the genetic makeup of PD will allow better understanding of the pathophysiology and help design specific treatments that alter the course of the disease. Future studies using cardiac 123I-MIBG SPECT imaging will provide valuable information to evaluate myocardial function and detect cardiac neuronal architecture with higher diagnostic performance than planar images13,14 according to the recommendations of the European Cardiovascular Committee.15 Further prospective studies in a larger group of patients with parkin mutations and other genetic forms of PD are required to confirm the findings of De Rosa et al.
- 15.Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010;37:1802-12.CrossRefPubMedGoogle Scholar